AKAN vs INM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AKAN exhibits severe financial distress, evidenced by a Piotroski F-Score of 3/9 (indicating weak operational health) and a lack of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company is unprofitable with negative margins across all key metrics, including a staggering -266.31% profit margin and -60.86% ROE. Despite a low Price/Book of 0.04 and a Graham Number of $281.01, the stock trades at $0.82—well below fair value—due to extreme operational failure and lack of sustainable growth. The 52-week price range shows a collapse from $46.45 to $0.81, reflecting a 100% decline over five years and confirming deep investor skepticism.
The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.
Compare Another Pair
Related Comparisons
AKAN vs INM: Head-to-Head Comparison
This page compares Akanda Corp. (AKAN) and InMed Pharmaceuticals Inc. (INM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.